Parfums Christian Dior – FDA 483, Jun 8, 2018
An FDA inspection of Parfums Christian Dior in St Jean de Braye, France, revealed significant deficiencies in their manufacturing of over-the-counter (OTC) drug products. The firm lacked adequate written procedures, process and equipment validation, and proper quality control oversight. Issues also included data integrity concerns, insufficient cleaning validation, and inadequate controls over components and rejected materials, indicating a broad failure to adhere to Good Manufacturing Practices.
ID · a955bdee-9f12-4bd8-b447-1e7ef258c1d2
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.